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Abstract
A recent paper by McKnight et al. in The Lancet has provided the first formal meta-analysis of the more common
adverse reactions to lithium. The authors analyzed 385 studies and focused mainly on the harmful effects of
lithium on the kidney, the thyroid and parathyroid glands, body weight, skin and congenital malformations. Their
contribution is important and welcome, but as a guide for practice, it needs to be complemented by other
relevant observations and individual patient-focused perspectives.
The findings from that meta-analysis somewhat underestimate the renal side-effects, and distort to some degree or
exclude other adverse effects. The glomerular filtration rate is reduced but not more than 0 to 5 ml/min/year of
observation; this may not fully reflect the present state of knowledge. A quarter of patients in the study had
abnormalities of the thyroid and/or parathyroid gland, and lithium was found to increase body weight significantly
less than did olanzapine. Unfortunately, the authors did not consider the observations from spontaneous reporting
systems, which may have changed the picture.
We feel that some specific limitations of the study were related to the inclusion of patients regardless of adequacy
of treatment, quality of monitoring, drug combinations, age and sex, and stabilization response.
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Introduction
In all treatment guidelines for bipolar disorder (BD),
lithium has been recommended as a first-line maintenance
treatment. Some directives have gone further; recent evi-
dence-based and consensus-based German guidelines [1]
firmly endorse lithium salts as the only first-line mainte-
nance treatment in BD, and some investigators qualify
lithium as the only proven mood stabilizer [2]. However,
the potential side-effects and risks of lithium treatment
may at times make the implementation of these recom-
mendations in daily practice challenging.
The adverse effects (AEs) and all practical aspects of
lithium treatment are detailed in a comprehensive text-
book published in 2006 [3]. In six chapters, the book sum-
marizes the toxicological aspects of lithium treatment, and
provides practical recommendations for the safe use of
lithium salts in acute and long-term treatment. However,
the recent paper by McKnight et al., a research group
from Oxford [4]. has provided the first formal meta-analy-
sis of the more common AEs to lithium. This contribution
is new, important, and welcome. However, as a guide for
practice, such statistical analysis, because of the limitations
outlined below, needs to be complemented by other rele-
vant observations and individual patient-focused perspec-
tives. Taking this into account it seems, as we explain
later, that the findings from this meta-analysis somewhat
underestimate the renal side-effects and distort to some
degree or exclude other AEs.
Lithium and renal function
For the meta-analysis, nearly 6000 publications on various
aspects of potential lithium toxicity were screened, and
385 studies published in English, French and German
were included in their analysis. The report focuses on the
harmful effects of lithium on the kidney, the thyroid and
parathyroid, body weight, skin and congenital malforma-
tions. The authors searched primarily for controlled
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studies (22 randomized controlled trials (RCTs), prospec-
tive cohort studies, and case-control studies) but, in their
absence, also considered prospective observations and case
reports. Expanding the review beyond time-limited RCTs
is important because lithium treatment is usually applied
long term, and the initial and later side-effects differ. Such
an inclusive approach is in accordance with the policy of
most regulatory agencies, and is important for early identi-
fication of suspected AEs. Unfortunately, the authors did
not consider data from national or international sponta-
neous reporting systems for AEs.
McKnight et al. [4] discuss in detail the effects of
long-term lithium on renal function particularly. They
found that the reduction in the glomerular filtration rate
(GFR) was relatively small: 0 to 5 ml/min over each year
of observation, while urinary concentration ability was
on average reduced by 15%. As for long-term conse-
quences, the authors refer to a Swedish registry showing
that renal failure occurred in 18 of 3369 patients (0.5%),
that is, double the incidence in the general Swedish
population. McKnight et al. [4] conclude that ‘there is
little evidence for a clinically significant reduction in
renal function in most patients, and the risk of end-
stage renal failure is low.’
However, a meta-analysis is not equipped to assess this
issue fully. Reduced GFR, or rather end-stage renal failure,
only starts appearing in some patients after continuous
treatment for more than 15 to 20 years, whereas meta-
analyses will unavoidably include numerous patients trea-
ted for shorter periods. In this respect, more informative
are the recent studies [5-8] on prolonged lithium treat-
ment that have shown that the risk of renal end-stage fail-
ure might not be that rare, even in subjects properly
managed on lithium for more than 15 years. Unfortu-
nately, regular kidney function monitoring is often lacking
in practice: a large French study shockingly showed that
serum creatinine serum levels had not been performed in
40% of patients on lithium between 1997 and 2004 [9].
More informative observations from other investigators
are needed. The International Group for The Study of
Lithium-Treated Patients (IGSLI) has been concerned
about these issues, and at present is stimulating and sup-
porting studies in lithium centers from which data are
available for important clinical variables, longitudinal
courses, and renal examinations of regularly monitored
patients. The findings should allow formulation of practi-
cal recommendations for the rational management of
individual patients. When to discontinue lithium because
of serious renal problems is a particularly vexing pro-
blem. This decision cannot be made solely by the treating
nephrologist, but also requires expert psychiatric evalua-
tion of the benefits and true risks that the individual
patient can expect from his/her lithium medication in
future years [10,11].
Endocrine effects and weight gain
McKnight et al assessed the AEs of lithium on the thyr-
oid, as reported by 77 studies (including 4 RCTs) with
varying methodological approaches. The risk of clinical,
subclinical and laboratory (as measured by thyroid-sti-
mulating hormone levels) hypothyroidism was increased
by five times. As McKnight et al. point out, it was diffi-
cult to include some papers published more than 30
years ago because of difficulty in comparing the labora-
tory resultss. The meta-analysis also found that serum
parathormone and calcium levels increased by about
10%. Overall, a quarter of patients had abnormalities of
the thyroid and/or the parathyroid gland. Of practical
importance is the finding that stimulation of parathyroid
function is likely to be more common than assumed to
date. Regular monitoring of serum calcium levels should,
therefore, be mandatory, and if found to be consistently
raised, they should be properly managed [6].
In the meta-analysis, long-term lithium treatment was
found to produce modest but significant weight gain,
with an odds ratio of 1.89, and this was distinctly lower
than the weight gain induced by olanzapine. Weight gain
can be a problem with lithium treatment, but it is less
pronounced than with the most frequently prescribed
‘atypical’ neuroleptics [11]. The latter are prescribed
increasingly for patients with BD [12,13], and serious
concernshave already been expressed about this thera-
peutic strategy and its unfortunate metabolic effects
[14-17]. Furthermore, unlike atypical neuroleptics,
lithium has not been found to induce diabetes mellitus.
McKnight et al. mention that hair loss was described
mostly in case reports; in two RCTs, hair loss occurred in
3% to 8% of patients on lithium, compared with 0% to 6%
in the placebo group. Surprisingly, McKnight et. al. could
not find sufficient evidence for the existence of lithium-
induced skin abnormalities; however, a long series of case
reports (available online in the appendix of their paper)
tends to contradict their statistical finding.
We feel, and McKnight et al. readily admit, that their
meta-analysis has limitations, which include both the nat-
ure of the available data and the non-consideration of
potential confounding variables, and therefore, is likely to
lead to a biased estimation of important AEs. The claim
by McKnight et al that they undertook ‘a clinically infor-
mative systematic toxicity profile of lithium’ is only partly
fulfilled because the group failed to assess and discuss
many of the AEs of lithium that are particularly important
to patients and may influence compliance, such as gastro-
intestinal problems, tremor, cognitive impairments, ataxia,
or speech disorders. To give one example: in the German
spontaneous reporting system of adverse drug reactions,
tremor accounted for nearly 9% of the 654 reports
(received until 10 October 2008, referring to lithium
mono as well as combined treatment), changed gait and
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ataxia for more than 10%, and confusional states for 9.5%
(Drug Commission of the German Medical Association,
personal communication).
Below, we discuss several specific issues that need to
be considered critically.
1. Practicing clinicians are primarily interested in the
potential AEs experienced by properly treated
patients, that is, patients who are correctly selected
for long-term lithium treatment, are maintained on a
minimum effective dosage, and are regularly moni-
tored and managed. In this context, lithium treatment
generates AEs in a relatively small proportion of
patients. However, the reports included in the meta-
analysis unavoidably included numerous patients
with bipolar spectrum disorders for whom lithium
treatment was not the optimal treatment choice [18],
and who were treated by physicians with insufficient
experience in lithium treatment. Hence, an important
aspect of future work would be to compare the rates
of side-effects in specialized programs as opposed to
general psychiatric practice.
2. Sufficient information about dosage and serum
levels of lithium could not be taken into account
although the authors made efforts to exclude patients
with pre-existing lithium intoxication. Many side-
effects, including endocrine and metabolic effects are
dose-dependent, and therefore can often be controlled
by proper dose titration. Details on patient compliance
and the time intervals between lithium plasma levels
and AEs would have been important background
information, and their absence raises questions about
the validity of the data and the statistical processing.
This criticism was also raised by Malhi and Berk [19]
in the same issue of the journal. As clinicians, we often
come across referred patients whose dosage has not
been adjusted for many years, and they frequently
experience side-effects because their lithium levels are
frequently much higher than 1.0 mmol/l.
3. The potential confounding factors of age and sex on
lithium treatment could not be considered adequately
in the meta-analysis.
4. Another important piece of information for the
correct interpretation of side-effects is the patient’s
clinical response to long-term lithium treatment.
Non-responders develop side-effects distinctly more
frequently than responders, even at comparable
serum lithium levels [20].
5. There is also the problem of potentially harmful
co-medication. McKnight et al. did not elaborate on
whether co-prescription of potentially nephrotoxic
drugs (for example, antibiotics, cyclooxygenase-2
inhibitors) or compounds that can change the phar-
macokinetics of lithium was controlled for, as this
can be a strong potential confounding factor particu-
larly with regard to renal toxicity.
6. Finally, it remains unclear whether AEs such as
impaired thyroid function occurred during lithium
medication given alone or were seen during treat-
ment with thyroxin supplementation.
Conclusions
McKnight et al. have published an important and ambi-
tious study, which provides statistical data that were pre-
viously not available. The paper contributes significantly
to the understanding of some potential AEs of long-term
lithium treatment. However, for clinical practice, the
findings of this meta-analysis must be integrated with
other relevant observations including those from specia-
lized lithium centers and from national and international
spontaneous reporting systems, and caution is needed
because of the understandable limitations of the data
available for meta-analyses.
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